The ability of PARPs to modulate the TME highlights their importance not only in tumor biology but also within the therapeutic arena, suggesting that targeting PARP activity may improve the efficacy of both chemo-, radio- and immunotherapies by reshaping the TME to support anti-tumor immunity [135–137]. The gene discussed is PARP1; the disease is neoplasm.